Investerare
Investerare
AroCell’s acquisition of IDL Biotech in 2021 was the starting point for what we call today the new AroCell.
The merger of the two companies created a new stronger company with a broad product portfolio. On May 27, 2026, the company’s name was changed to IDL Diagnostics.
IDL Diagnostics develops, manufactures, and supplies diagnostic tests for cancer and bacterial infection. Our broad product portfolio is used by clinics and hospitals to ensure that patients receive the best possible treatment.
IDL Diagnostics has a complete infrastructure in-house, from research and production to sales and marketing. That makes us unique for a company of this size. We grow organically through growth in existing markets as well as opening new markets. We also develop new products that we can sell through our existing sales channels. Overall, we are well positioned for strong organic growth.
Our vision is to offer a product portfolio that in the best possible way contributes to creating the conditions for short treatment times and increased quality of life. We want to be the obvious choice within our segment in the markets where we are established. The market for our products is large and we are a smaller player with significant growth potential so far.
Financial Calendar
Latest Interim Report
Latest Annual Report
Om oss
Vi ger kunskap till beslut.
IDL Diagnostics är ett svenskt diagnostikföretag med visionen att förbättra övervakningen av onkologiska och bakteriella sjukdomar. Vi har en bred produktportfölj av IVD-tester som levererar högvärdig klinisk information för att upptäcka sjukdomar.
Onkologi
Diagnostik för onkologi
Cancer är en av de vanligaste dödsorsakerna i världen, trots att kunskapen ökar. För att förbättra behandlingen av cancerpatienter finns det ett tydligt behov av effektiva diagnostikverktyg för att fånga upp dessa viktiga kliniska data.
